Skip to main content
. 2021 Jul 19;12(1):274–290. doi: 10.1016/j.apsb.2021.07.009

Figure 9.

Figure 9

The primary cell lines [0001 (KRASG12A), 0034 (KRASG12R), 0037 (KRASG12D) and 0043 (KRASG12D)] from Ruijin Hospital were treated with 36l at various concentrations for 24, 48 and 72 h, respectively. The percentages of viability were measured by CCK8 method. All the studies with primary cell lines were approved by the Ruijin Hospital Ethics Committee.